What are the typical symptoms of pheochromocytoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Symptoms of Pheochromocytoma

Pheochromocytoma should be suspected in any patient presenting with the classic triad of episodic headaches, palpitations, and sweating, particularly when accompanied by severe or resistant hypertension. 1

Classic Symptom Triad

The most diagnostically significant symptoms are:

  • Headaches (pooled sensitivity 60.4%) 2
  • Palpitations (pooled sensitivity 59.3%) 2
  • Diaphoresis/sweating (pooled sensitivity 52.4%) 2

When all three symptoms occur together in a hypertensive patient, the diagnostic specificity approaches 90% for pheochromocytoma. 3 This classic triad has a positive likelihood ratio of 6.3 and a negative likelihood ratio of 0.14, making it highly valuable when present. 2

Cardiovascular Manifestations

Hypertension Patterns

  • Severe hypertension is the hallmark finding, with pooled sensitivity of 80.7% 1, 2
  • Resistant hypertension (systolic ≥190 mmHg despite multi-drug therapy) is particularly characteristic 3
  • Paroxysmal hypertension superimposed on sustained hypertension 1, 4
  • Importantly, approximately 15% of patients have no history of hypertension, making normotension insufficient to exclude the diagnosis 1

Cardiac Symptoms

  • Tachycardia and cardiac arrhythmias 1
  • Palpitations with or without chest pain 1
  • Systolic heart failure and ST-segment changes mimicking myocardial infarction 5
  • QT interval prolongation and rarely ventricular tachycardia 5
  • Signs of congestive heart failure on examination 1

Autonomic and Metabolic Symptoms

  • Anxiety attacks or sense of impending doom 1
  • Weight loss despite adequate caloric intake 1
  • Excessive sweating beyond what hypertension alone would cause 1
  • Facial flushing and intermittent pallor 3
  • Tremor and tremulousness 3, 6
  • Nausea accompanying hypertensive episodes 3

Episodic Nature

Approximately 95% of patients experience paroxysmal symptoms, while about 50% have sustained hypertension between episodes. 3 These "spells" or attacks can be:

  • Spontaneous or triggered by specific activities 7
  • Provoked by certain medications (see below) 1, 7
  • Associated with blood pressure lability 4

Physical Examination Findings

Key findings to assess include:

  • Blood pressure and pulse measurement in both upper and lower extremities 1
  • Orthostatic hypotension (sensitivity 23-50%, variable definitions) 2
  • Displaced apical impulse suggesting left ventricular hypertrophy from chronic catecholamine exposure 3
  • Persistent tachycardia despite beta-blockade 3
  • Excessive sweating and anxiety on examination 1
  • Skin stigmata of neurofibromatosis (café-au-lait spots, neurofibromas) if associated with genetic syndrome 4

Atypical Presentations

The clinical manifestations can be highly variable and may mimic many other diseases. 6 Some patients present with:

  • No typical triad symptoms 8
  • Absence of obvious clinical signs with only imaging and biochemical abnormalities 8
  • Cardiovascular emergencies without preceding typical symptoms 5
  • Incidental adrenal mass discovered on imaging for unrelated reasons 1, 7

Critical Clinical Pitfalls

Medication-Provoked Symptoms

Certain medications can trigger catecholamine release and should raise suspicion:

  • Tricyclic antidepressants 1
  • Decongestants and sympathomimetics 1
  • Amphetamines and other stimulants 1
  • Metoclopramide and other dopamine antagonists 7

Dangerous Management Errors

Beta-blocker monotherapy in untreated pheochromocytoma is potentially hazardous and may precipitate unopposed alpha-adrenergic stimulation leading to hypertensive crisis. 3 This occurs because blocking beta-2 mediated vasodilation leaves alpha-1 vasoconstriction unopposed.

When to Suspect Pheochromocytoma

Test for pheochromocytoma in these clinical settings 7:

  • Paroxysmal symptoms of headache, palpitations, and sweating
  • Resistant hypertension despite adequate therapy
  • Adrenal incidentaloma with or without hypertension
  • Young patients (<40 years) with severe hypertension 3
  • Family history of pheochromocytoma or associated syndromes (MEN 2, von Hippel-Lindau, neurofibromatosis, familial paraganglioma) 1, 9
  • Previous history of pheochromocytoma 7

Diagnostic Delay

The mean interval from symptom onset to definitive diagnosis is approximately 3 years, highlighting the importance of clinical recognition. 3 Autopsy series demonstrate that pheochromocytomas contributed to 55% of deaths and were clinically unsuspected in 75% of cases, underscoring the frequency of missed diagnoses. 3

Initial Diagnostic Approach

When pheochromocytoma is suspected based on symptoms:

  • Measure plasma free metanephrines (99% sensitivity, 89% specificity) as the preferred initial test 3
  • Alternatively, obtain 24-hour urinary fractionated metanephrines (77-97% sensitivity, 69-98% specificity) 1
  • Discontinue interfering medications before testing: tricyclic antidepressants, decongestants, amphetamines, reserpine, and phenoxybenzamine 1, 3
  • Plasma metanephrine levels exceeding 3-4 times the upper reference limit are highly diagnostic 1, 3

References

Guideline

the american association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2009

Guideline

Pheochromocytoma: Evidence‑Based Diagnostic and Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2014

Research

Progress in treatment and follow-up of pheochromocytoma.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2025

Research

Pheochromocytoma: a review.

Maturitas, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.